Johnson & Johnson EVP Sells JNJ Shares Worth $3 Million
John C. Reed, Executive Vice President, Innovative Medicine and R&D of Johnson & Johnson ( NYSE:JNJ ) , executed an open market sale of 19,137 shares as disclosed in a Form 4 filed July 18, 2025.How does this transaction compare to John C.
Got $1,000? 3 Dividend Stocks to Buy and Hold Forever
Dip into a beaten-down market sector for deals on some proven winners.
Kenvue ( KVUE ) Q2 Sales Drop 4%
Kenvue ( NYSE:KVUE ) , the consumer health company best known for brands like Tylenol and Band-Aid, reported its earnings for the second quarter on August 7, 2025. The main news from the release: Non-GAAP earnings per share reached $0.29, narrowly beating analyst forecasts of $0.28 ( non-GAAP ) , ...
Kenvue ( KVUE ) Q2 Earnings Top Estimates
Kenvue (KVUE) delivered earnings and revenue surprises of +3.57% and -0.51%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Edgewell Personal Care ( EPC ) Misses Q3 Earnings and Revenue Estimates
Edgewell Personal (EPC) delivered earnings and revenue surprises of -8.91% and -4.54%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Countdown to Kenvue ( KVUE ) Q2 Earnings: A Look at Estimates Beyond Revenue and EPS
Besides Wall Street's top-and-bottom-line estimates for Kenvue (KVUE), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2025.
Analysts Estimate Kenvue ( KVUE ) to Report a Decline in Earnings: What to Look Out for
Kenvue (KVUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should J&J Stock Be in Your Portfolio After Q2 Beat & Guidance Raise?
JNJ jumps over 6% on Q2 earnings beat and full-year guidance increase, driven by strong pharma sales and improved MedTech sales.
Deal Dispatch: Del Taco Tanks, Tylenol Maker Aches, Joyebells Cooked - Clearside Biomedical ( NASDAQ:CLSD ) , Bausch & Lomb ( NYSE:BLCO )
Tylenol and Listerine maker Kenvue Inc. KVUE just named board member Kirk Perry as interim CEO, replacing Thibaut Mongon, as part of a strategic review to boost shareholder value.
4 Mid-Cap Value Mutual Funds for Long-Term Gains
VASVX, TAMVX, TRVPX and FVLKX offer mid-cap value exposure with solid returns, low fees, and long-term growth potential.
Is Johnson & Johnson a Good Dividend Stock to Buy Now?
For decades, Johnson & Johnson ( NYSE: JNJ ) stock was favored by investors seeking steady gains. Looking at its post-COVID-19 performance, though, steady gains aren't what investors received.When the market closed on Tuesday, July 15, shares of Johnson & Johnson or J&J, were down 7.5% in the ...
JNJ Begins Drug Sector Q2 Earnings With a Beat & Guidance Raise
JNJ tops second-quarter estimates and raises 2025 guidance as Innovative Medicines outperforms and MedTech gains momentum.
3 Magnificent S&P 500 Dividend Stocks Down 16% to 20% to Buy and Hold Forever
If you look at the history of the S&P 500 ( SNPINDEX: ^GSPC ) index, dividend stocks have played a significant role in shareholder returns. Over the past 25 years, for example, while the S&P 500 rose over 300%, the power of dividend reinvestment and compounding pushed its total returns to over ...
Company News for Jul 15, 2025
Companies in The News Are: ...
Want to Generate at Least $1,000 in Passive Income Per Year? Invest $26,000 in This Dividend King Stock.
The stock market has historically been a highly effective tool for compounding wealth over time. Another way to use the stock market to achieve your financial goals is to generate income from dividend stocks.Sometimes, it can make sense to target a stodgy company with a high yield, rather than ...
Should J&J Stock Be in Your Portfolio Ahead of Q2 Earnings?
JNJ eyes Q2 growth with strong drug sales and new launches, but Stelara biosimilars and MedTech headwinds loom.
What Is Considered a Good Dividend Stock? 3 Healthcare Stocks That Fit the Bill
A steady dose of quality companies will keep your portfolio growing big and strong.
Looking to Generate Passive Income? Consider These 3 Rock-Solid Dividend King Stocks
Investing in the stock market over a long-term time horizon can be an excellent way to compound your savings. However, the path toward unlocking significant gains can be marked by numerous ups and downs.Risk-averse investors or those nearing retirement may prefer dividend stocks over growth ...
Pioneering New Study Finds Most U.S. Babies Lack Key Gut Bacteria, Increasing Risk for Allergies and Other Chronic Health Issues
Initial findings published today in Communications Biology - a Nature portfolio journal - show that 76% of infants in the U.S. are deficient in Bifidobacterium, a gut microbiome genus responsible for the utilization of human milk oligosaccharides ( HMOs )
J&J Adds More Than $15B in Six Months: How to Play JNJ Stock?
JNJ stock added $15B in market value in six months as new drug launches offset MedTech and Stelara headwinds.
Johnson & Johnson Unusual Options Activity For June 20 - Johnson & Johnson ( NYSE:JNJ )
Whales with a lot of money to spend have taken a noticeably bearish stance on Johnson & Johnson. Looking at options history for Johnson & Johnson JNJ we detected 9 trades. If we consider the specifics of each trade, it is accurate to state that 33% of the investors opened trades with bullish ...
How Is The Market Feeling About Kenvue? - Kenvue ( NYSE:KVUE )
Kenvue's KVUE short percent of float has fallen 34.12% since its last report. The company recently reported that it has 32.46 million shares sold short, which is 2.24% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.91 days to cover their ...
2 Dividend Stocks to Buy and Never Sell
There are excellent reasons to invest in dividend stocks, including the fact that they typically outperform their non-dividend-paying peers in delivering strong market returns over long periods.However, just because a company pays a dividend doesn't make it attractive in and of itself.
A Look Into Kenvue Inc's Price Over Earnings - Kenvue ( NYSE:KVUE )
Looking into the current session, Kenvue Inc. KVUE shares are trading at $21.43, after a 1.36% decrease. Over the past month, the stock decreased by 8.61%, but over the past year, it actually increased by 16.05%.
Asia Markets Rise, Europe Follows; Dollar Pressured As Trade Talks In Focus - Global Markets Today While US Slept - SmartETFs Asia Pacific Dividend Builder ETF ( ARCA:ADIV )
Crude Oil WTI traded higher by 0.33% at $63.62/bbl, and Brent was up 0.35% at $65.68/bbl. Gold traded higher by 0.24% to $3,385.27, Silver rose 0.12% to $34.675, and Copper was up 0.88% to $4.8765. Rebound or breakdown? See how Matt Maley is trading June's market volatility, live this Wednesday, ...
Small Caps Surge, Dollar General Stock Eyes Best Day, Crude Hits 2-Week Highs: What's Driving Markets Tuesday? Wall Street Gains As Tariff Delay, Strong Jobs Data Lift Small Caps - Cameco ( NYSE:CCJ )
Small caps led gains with Russell 2000 up 1.9%, signaling renewed confidence in U.S. economic resilience. Energy stocks surge as oil jumps 5% in two days amid supply concerns from Ukraine-Russia tensions. Get access to the leaderboards pointing to tomorrow's biggest stock movers.
Why Dan Loeb Just Made Kenvue One Of His Top Holdings - Kenvue ( NYSE:KVUE )
Dan Loeb's Third Point acquired an 8.9 million stake in Kenvue in Q1 2025, making it a top five holding. Kenvue updated its FY25 outlook to reflect higher tariff costs and currency impacts, while its Q1 sales beat consensus.
P/E Ratio Insights for Kenvue - Kenvue ( NYSE:KVUE )
In the current market session, Kenvue Inc. KVUE stock price is at $23.51, after a 0.92% decrease. However, over the past month, the company's stock went up by 2.01%, and in the past year, by 26.39%.
This Healthy High-Yielding Dividend Stock Just Increased Its Payment for the 48th Year in a Row
Medtronic ( NYSE: MDT ) has been a dividend stalwart for decades. The medical device maker recently raised its dividend payment, extending its growth streak to 48 straight years. That means it is two years away from joining dividend royalty as a Dividend King.
Billionaire Dan Loeb Sold His Fund's Entire Stake in Tesla and Is Piling Into Wall Street's Preeminent Artificial Intelligence ( AI ) Stock
Third Point's Dan Loeb is swapping out one of Wall Street's most influential businesses for another innovative leader.
JNJ Down 6% in 3 Months: How to Play the Stock Amid Various Challenges
While J&J's Innovative Medicines segment is showing a growth trend, the MedTech unit's slowdown is a concern ...
Is Kenvue Gaining or Losing Market Support? - Kenvue ( NYSE:KVUE )
Kenvue's KVUE short percent of float has risen 61.49% since its last report. The company recently reported that it has 40.73 million shares sold short, which is 2.81% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.14 days to cover their ...
Rocket Doctor Partners with Melanoma Canada to Expand Access to Follow-Up Care for At-Risk Patients
New collaboration will connect patients flagged during mobile skin cancer screenings with Rocket Doctor physicians across Ontario, Alberta, and British Columbia ...
Market Whales and Their Recent Bets on JNJ Options - Johnson & Johnson ( NYSE:JNJ )
Deep-pocketed investors have adopted a bullish approach towards Johnson & Johnson JNJ, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today.
Loeb's Third Point Exits Meta, Tesla, Rotates Into Staples, Telecom, Industrials - Apollo Global Management ( NYSE:APO ) , Amazon.com ( NASDAQ:AMZN )
Third Point significantly reduced its stakes in Microsoft, Intercontinental Exchange, and Amazon during the first quarter of 2025. The firm initiated or increased its positions in Kenvue, AT&T, United States Steel, and NVIDIA in the same period.
The Smartest Dividend Stocks to Buy With $5,000 Right Now
If you have some spare cash, it's a great idea to put it into some dividend-paying stocks. They're a useful source of passive income that can help supplement your earned income. And if this income stream becomes large enough over time, you can rely on it to enjoy a comfortable retirement.The best ...
Neutrogena-Maker Kenvue Beats Profit Forecast, Ups Sales Outlook - Kenvue ( NYSE:KVUE )
Q1 revenue hit $3.74 billion vs. $3.68 billion consensus; sales down 3.9% YoY on lower volume and currency impact. Adjusted operating margin fell to 19.8% from 22.0% YoY; self-care segment flat at $1.67 billion. Don't miss this list of 10 overlooked stocks-including one paying a 9% ...
Here are the top 10 things we're watching in the stock market Thursday
The market is headed for a strong open today after President Trump said the U.S. has made a trade deal with the U.K.
Kenvue ( KVUE ) Beats Q1 Earnings and Revenue Estimates
Kenvue (KVUE) delivered earnings and revenue surprises of 9.09% and 1.70%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Edgewell Personal Care ( EPC ) Q2 Earnings and Revenues Lag Estimates
Edgewell Personal (EPC) delivered earnings and revenue surprises of -3.33% and 1.69%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
How Is The Market Feeling About Kenvue? - Kenvue ( NYSE:KVUE )
Kenvue's KVUE short percent of float has fallen 12.56% since its last report. The company recently reported that it has 33.23 million shares sold short, which is 1.74% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.87 days to cover their ...
Ahead of Kenvue ( KVUE ) Q1 Earnings: Get Ready With Wall Street Estimates for Key Metrics
Beyond analysts' top -and-bottom-line estimates for Kenvue (KVUE), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2025.
Here Are All the Dividend Kings Beating the S&P 500 in 2025 -- and the 2 That Are the Best Stocks to Buy Now
The S&P 500 has bounced back somewhat after sinking nearly 19% below its previous high following President Trump's "Liberation Day" reciprocal tariffs announcement in April. However, the major index is still in negative territory for the year, along with many stocks.One group of stocks is easily ...
3 Dividend Stocks You Can Be Comfortable Buying and Holding, Even in a Recession
The broader stock market indexes have recovered nicely in recent weeks. However, some investors may still fear that the impact of tariffs could lead the economy into a recession, which could have longer-lasting effects on earnings and stock prices.Visa ( NYSE: V ) , Kenvue ( NYSE: KVUE ) , and ...
2 Stocks Down 89% and 15% to Buy Right Now
A third of the year is now over, and the stock market has seen incredible levels of volatility across the stretch. The S&P 500 index is down roughly 9.5% from its high as of this writing, and the Nasdaq Composite index has fallen 13.5%.
Kenvue ( KVUE ) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
Kenvue (KVUE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's How You Should Play JNJ Stock After Q1 Earnings Beat
Those who own JNJ stock may stay invested for some time to see how the company achieves growth in 2025 amid the various challenges.
This Super-Safe High-Yield Stock Just Extended Its Dividend Growth Streak to 63 Years in a Row
Johnson & Johnson ( NYSE: JNJ ) continues to treat its investors like royalty. The healthcare behemoth recently gave them another raise, increasing its dividend payment by 4.8%. That extended its dividend growth streak to an impressive 63 years in a row, keeping it in the elite group of Dividend ...
JNJ Tops Q1 Earnings, Ups '25 Sales View to Include Intra-Cellular Deal
J&J beats first-quarter earnings and sales estimates. It raises sales guidance for 2025 to reflect the addition of Caplyta from the Intra-Cellular acquisition.
Buy, Sell or Hold J&J Stock? Key Tips Ahead of Q1 Earnings
JNJ's Innovative Medicines unit sales are expected to have been driven by drugs like Darzalex and Tremfya. We do not expect any improvement in MedTech sales.
